Moderna’s investigational messenger RNA (mRNA) vaccine for influenza — mRNA-1010 — has shown mixed efficacy in interim results from a phase 3 clinical trial.

The vaccine candidate targets four influenza strains, including influenza A/H1N1, A/H3N2,  influenza B/Yamagata- and B/Victoria. The interim data showed strong efficacy against the A/H3N2 and A/H1N1 strains but less against the two others.

The trial included more than 6,000 adults in Argentina, Australia, Colombia, Panama and the Philippines during the Southern Hemisphere influenza season.